Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott F Huntington

Showing results (11-20 of 81) with videos related to

Pageof 9
Sort By:
Leukemia & Lymphoma|January 21, 2012
Toxicities and outcomes among septuagenarians and octogenarians with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapyScott F Huntington, Mahsa S Talbott, John P Greer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2018
Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin LymphomaScott F Huntington, Gottfried von Keudell, Amy J Davidoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2021
Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple MyelomaKishan K Patel, Smith Giri, Terri L Parker, et al.
Leukemia & Lymphoma|December 16, 2021
Treatment patterns, economic burden, and overall survival in US Medicare Advantage beneficiaries newly diagnosed with acute myeloid leukemia (AML) in 2015-2020Scott F Huntington, Michael P Ingham, Linda Okonkwo, et al.
Journal of the American Geriatrics Society|March 7, 2023
Functional status and therapy for older adults with diffuse large B-cell lymphoma in nursing homes: A population-based studyMengyang Di, Tamra Keeney, Emmanuelle Belanger, et al.
Blood|June 11, 2020
Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemiaKishan K Patel, Iris Isufi, Shalin Kothari, et al.
Journal of Pain and Symptom Management|January 14, 2020
Perspectives Regarding Hospice Services and Transfusion Access: Focus Groups With Blood Cancer Patients and Bereaved CaregiversCatherine Henckel, Anna Revette, Scott F Huntington, et al.
Blood Advances|February 16, 2021
Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemiaKishan K Patel, Amer M Zeidan, Rory M Shallis, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 21, 2024
Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKisPatrick Squires, Justin Puckett, Katherine Elizabeth Ryland, et al.
The American Journal of Managed Care|June 9, 2016
High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemiaJalpa A Doshi, Pengxiang Li, Hairong Huo, et al.
Pageof 9

Showing results (11-20 of 81) with videos related to

Sort By:
Pageof 9
Leukemia & Lymphoma|January 21, 2012
Toxicities and outcomes among septuagenarians and octogenarians with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapyScott F Huntington, Mahsa S Talbott, John P Greer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2018
Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin LymphomaScott F Huntington, Gottfried von Keudell, Amy J Davidoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2021
Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple MyelomaKishan K Patel, Smith Giri, Terri L Parker, et al.
Leukemia & Lymphoma|December 16, 2021
Treatment patterns, economic burden, and overall survival in US Medicare Advantage beneficiaries newly diagnosed with acute myeloid leukemia (AML) in 2015-2020Scott F Huntington, Michael P Ingham, Linda Okonkwo, et al.
Journal of the American Geriatrics Society|March 7, 2023
Functional status and therapy for older adults with diffuse large B-cell lymphoma in nursing homes: A population-based studyMengyang Di, Tamra Keeney, Emmanuelle Belanger, et al.
Blood|June 11, 2020
Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemiaKishan K Patel, Iris Isufi, Shalin Kothari, et al.
Journal of Pain and Symptom Management|January 14, 2020
Perspectives Regarding Hospice Services and Transfusion Access: Focus Groups With Blood Cancer Patients and Bereaved CaregiversCatherine Henckel, Anna Revette, Scott F Huntington, et al.
Blood Advances|February 16, 2021
Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemiaKishan K Patel, Amer M Zeidan, Rory M Shallis, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 21, 2024
Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKisPatrick Squires, Justin Puckett, Katherine Elizabeth Ryland, et al.
The American Journal of Managed Care|June 9, 2016
High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemiaJalpa A Doshi, Pengxiang Li, Hairong Huo, et al.
Pageof 9